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Abstract
Lysophosphatidic acid (LPA) is an agonist for peroxisome proliferator activated receptor-c (PPARc). Although glycerol-3-
phosphate acyltransferase-1 (GPAT1) esterifies glycerol-3-phosphate to form LPA, an intermediate in the de novo synthesis
of glycerolipids, it has been assumed that LPA synthesized by this route does not have a signaling role. The availability of
Chinese Hamster Ovary (CHO) cells that stably overexpress GPAT1, allowed us to analyze PPARc activation in the presence
of LPA produced as an intracellular intermediate. LPA levels in CHO-GPAT1 cells were 6-fold higher than in wild-type CHO
cells, and the mRNA abundance of CD36, a PPARc target, was 2-fold higher. Transactivation assays showed that PPARc
activity was higher in the cells that overexpressed GPAT1. PPARc activity was enhanced further in CHO-GPAT1 cells treated
with the PPARc ligand troglitazone. Extracellular LPA, phosphatidic acid (PA) or a membrane-permeable diacylglycerol had
no effect, showing that PPARc had been activated by LPA generated intracellularly. Transient transfection of a vector
expressing 1-acylglycerol-3-phosphate acyltransferase-2, which converts endogenous LPA to PA, markedly reduced PPARc
activity, as did over-expressing diacylglycerol kinase, which converts DAG to PA, indicating that PA could be a potent
inhibitor of PPARc. These data suggest that LPA synthesized via the glycerol-3-phosphate pathway can activate PPARc and
that intermediates of de novo glycerolipid synthesis regulate gene expression.
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Introduction
Peroxisome proliferator activated receptor-c (PPARc)i sa
nuclear receptor that is highly expressed when pre-adipocytes
differentiate into adipocytes [1]. PPARc regulates gene expression
by forming a heterodimer with the retinoid6receptor (RXR) and
binding to PPAR response elements (PPRE) in the promoter
region of target genes. Genes that are regulated by PPARc are
primarily involved in adipocyte differentiation and fatty acid
metabolism [1]. Ligands for PPARc include polyunsaturated fatty
acids [2] and synthetically derived thiazolidinedione (TZD) ligands
for PPARc that improve insulin sensitivity in patients with type 2
diabetes [1].
Lysophosphatidic acid (LPA) derived from hydrolysis of plasma
membrane phospholipids is well established as a ligand for specific
G-coupled cell-surface LPA receptors that generate an intracellu-
lar signal cascade that enhances cell proliferation [3]. Studies have
suggested that exogenous LPA might also enter cells to activate
PPARc because LPA can bind to and displace rosiglitazone from
PPARc. Further, when LPA enters RAW264.7 monocytes, it
activates a PPRE reporter driven by a PPARc expression vector
[4]. Although the naturally occurring ether analog of LPA, 1-O-
octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), can enter
cells and is a ligand for purified PPARc (Kd ,60 nM), the entry of
LPA is more problematic [5]. Studies showing that LPA can
activate the intracellular PPARc reporter required dimethyl
sulfoxide (DMSO) and tridentate sulfonamid to enhance the
transport of exogenously added LPA across the cell membrane
[4,6]. Thus, although LPA can clearly activate PPARc [7], it is not
certain that exogenous LPA would normally function as a major
physiological activator of PPARc. Most LPA produced within cells
is synthesized as an intermediate in the pathway of triacylglycerol
and phospholipid biosynthesis, but it has been generally assumed
that LPA formed by de novo synthesis from glycerol-3-phosphate
(Fig. 1) has a role in lipid synthesis but not in signaling [8].
LPA is the direct product of glycerol-3-phosphate acyltransfer-
ase (GPAT), the rate-limiting step in glycerolipid synthesis [9]
(Fig. 1). Because the absence of the mitochondrial isoform
GPAT1 from liver causes a 50% decrease in LPA content [10],
whereas adenovirus-mediated overexpression of GPAT1 increases
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overexpresses GPAT1 [12] to determine whether endogenously
synthesized LPA could act as a PPARc agonist. CHO-GPAT1
cells have a 3.8-fold increase in GPAT1 activity, contain a 2.7-fold
higher triacylglycerol mass than control cells, and incorporate 3.4-
fold more [
14C]oleate into triacylglycerol, suggesting that the
intermediates of glycerolipid synthesis might be higher than
normal and that LPA levels might be elevated. We now provide
evidence that LPA synthesized intracellularly via the pathway of
triacylglycerol and phospholipid biosynthesis can activate PPARc
and that PA may inhibit PPARc activity.
Methods
Cell Culture
Chinese hamster ovary cells (CHO) (CHO-K1, #CCL-61,
ATTC) were maintained in MEM with 10% heat-inactivated fetal
bovine serum, 100 units/mL penicillin and 100 mg/mL strepto-
mycin (normal medium) at 37uC, 5% CO2. CHO cells that stably
overexpress GPAT1 (CHO-GPAT1 cells) [12] were maintained in
the same medium with 600 mg/mL G418 until studied. Expression
of GPAT1 in CHO-GPAT1 cells is controlled by the pTet-Off
plasmid (CLONTECH), so GPAT1 expression is repressed when
doxycycline is present.
Plasmids
pSG5 expression vectors encoding hPPARc and mRXRa
[13,14] and the PPRE reporter plasmid ACOX2-tk-CAT
[13,15] were described previously. The pShuttle2 expression
vector encoding hAGPAT2 was a generous gift from Dr. A. K.
Agarwal (University of Texas Southwestern Medical Center) [16].
pcDNA3-DGKa WT and pcDNA3-DGKaD 196, encoding
constitutively active DGKa, were generous gifts from Dr. J. P.
Walsh (Indiana University School of Medicine) [17]. The internal
control reporter construct pRL-SV40 was from Promega.
pcDNA3.1 was from Invitrogen.
Transactivation Assay
CHO cells and CHO-GPAT1 cells were plated at 4610
5 cells/
well in 6-well dishes. After 24 h, cells were transfected in Opti-
MEM (GIBCO) with equal concentrations (0.4 mg) of expression
vectors (PPARc and RXR) and a PPRE-CAT reporter vector
using FuGENE 6 (Roche). Transfections of PPARc were in
medium containing delipidated serum (HyClone). To monitor
transfection efficiency, 0.1 mg pRL-SV40 was transfected as an
internal luciferase control. Equal concentrations of DNA were
transfected into cells at all times. As a control, cells that were not
transfected with either the AGPAT2 expression vector or the
vector expressing constitutively active DGKa were transfected
with equal amounts of a negative control, i.e., pcDNA3.1 or
pcDNA3-DGKa WT, respectively. Twenty-four hours after
transfection, cells were treated with troglitazone (Cayman
Chemical Company) or dimethyl sulfoxide (vehicle control). After
further incubation for 24 h, cells were assayed for Renilla
luciferase (LUC) (Renilla Luciferase Assay System; Promega).
Chloramphenicol acetyltransferase (CAT) activity, a measure of
PPRE activity, was determined using the CAT enzyme-linked
immunosorbent assay kit (Roche). CAT reporter activity relative
to LUC activity was calculated and plotted. Experiments were
performed in triplicate, and for the statistical analysis, either
Student’s t-test, assuming equal variances, or ANOVA followed by
multiple comparison of means with Bonferroni’s multiple
comparison test was used (GraphPad Prism, version 4 statistical
software; GraphPad Software). Representative figures from each
experiment are shown. Variation of luciferase sensitivity between
experiments was responsible for the difference in the scale of
relative CAT activity.
Preparation of Fatty Acid:BSA Complex
Fatty acids were prepared in 20 mM stock solutions. Bovine
serum albumin (BSA) (12.5%; essentially fatty acid-free) was
prepared in MEM containing antibiotics and delipidated serum.
Just before cell treatment, fatty acids were bound to BSA at a final
concentration of 0.5 mM fatty acid and 1% BSA [18]. Cells were
treated with a final concentration of 250 mM fatty acid.
Preparation of Extracellular LPA and PA
1-Oleoyl-2-hydroxy-sn-glycero-3-phosphate (18:1 LPA) and 1,2-
dioleoyl-sn-glycero-3-phosphate (18:1 PA) (Avanti Polar Lipids,
Inc.) were dried under nitrogen and dissolved in 0.1% BSA
immediately before use. Dioctanoyl glycerol (diC8:0) (Sigma) was
dissolved in dimethyl sulfoxide before use.
Mass Spectrophotometry
CHO and CHO-GPAT1 cells grown to confluence in 150 mm
dishes, washed with ice cold PBS, and scraped into 1 mL ice cold
PBS. Cells were counted and stored at 280uC, and acyl-CoAs
were extracted [19,20]. To extract PA and LPA, cells were
sonicated and homogenized in 1 mL of phosphate buffer (40 mM
Na2HPO4, 30 mM citric acid, pH 4.0) plus an internal standard
(heptadecanoyl-LPA). Two milliliters of butanol were added, and
cells were rehomogenized and centrifuged at 4000 rpm for
15 min. Supernatants containing the LPA and PA were dried,
redissolved in 1 mL water and applied to an Oasis HLB column.
The column was washed once with water, and then LPA and PA
were eluted with methanol. Authentic standards (acyl-CoA, TAG:
Figure 1. Pathway of glycerolipid synthesis. AGPAT, acyl-glycerol-
3-phosphate acyltransferase; CL, cardiolipin; DGK, diacylglycerol kinase;
GPAT, glycerol-3-phosphate acyltransferase; PC, phosphatidylcholine;
PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phospha-
tidylinositol; PS, phosphatidylserine.
doi:10.1371/journal.pone.0018932.g001
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Co.) were used for quantification. Results are expressed as
nanomoles analyte per gram protein extract. Analysis was
performed with a bench-top tandem mass spectrometer API3000
(Perkin-Elmer Sciex) interfaced with TurboIonspray ionization
source. The mobile phase was methanol and H2O with an
isocratic gradient (50/50). Acyl-CoAs were ionized in negative
ionspray mode [20]. Doubly charged ions and corresponding
product ions were chosen as transition pairs for each acyl-CoA
species for selective reaction monitoring quantitation. LPA and PA
were ionized in TurboIonspray mode with MRM quantification of
the parent ion (minus phosphate) and corresponding product ions
of the fatty acid moiety.
PPARc LBD LEADseeker Scintillation Proximity Assay
Storage buffer [50 mM Tris pH 8, 50 mM KCl (100 mL)] was
added to 500 mg of streptavidin-coated LEADseeker SPA beads
(Amersham). After mixing for 30 min on a Nutator platform, the
beads were centrifuged at 1500 rpm.for 10 min at 22uC. The bead
pellet was resuspended in 100 mL of storage buffer at 5 mg/mL.
At room temperature, the bead stock (5 mL) was diluted with
7.5 mL of assay buffer (50 mM Tris pH 8, 50 mM KCl, 2 mM
EDTA, 5 mM CHAPS, 0.1 mg/mL BSA, 10 mM DTT) and
120–150 nM of biotinylated PPARc LBD [21] was added to a
final volume of 12.5 mL. The slurry was incubated for at least one
hour with gentle agitation and then centrifuged at 1500 rpm for
10 min at 22uC. The bead pellet was gently washed with 12–
15 mL of assay buffer, centrifuged as described previously,
resuspended (45 mL assay buffer, 5 mL 1 mM biotin), and
incubated for 1.5 h with gentle agitation.
Radioligand ([
3H]rosiglitazone) stock was diluted to 150 nM in
assay buffer, mixed with an equal volume of receptor-coated
beads, incubated for 5 min, and added (10 mL) to 384-well assay
plates (NUNC, 264675) containing 0.1 mL of compound. Final
assay concentrations were 75 nM radioligand and 0.25 mg/mL
PPARc-LBD-coated beads. Fatty acids were diluted in ethanol:
water (1:1) with a starting concentration of mM and assayed as
dose response curves. After a 2–15 h incubation at RT, covered
and in the dark, the signal was determined at 613 nm using a
Viewlux plate imager (Perkin Elmer). Non-specific binding was
determined with 20 mM unlabeled rosiglitazone.
Total RNA Extraction and Quantitative RT-PCR
CHO and CHO-GPAT1 cells were grown to 90% confluence,
and RNA was extracted (RNeasy Midi Kit, Qiagen). Forward and
reverse primers for mouse GPAT1 were 59-ATGGACGCAAA-
GACATTCTGT-39 and 59-AAGATCTCCAGGAACTGCTG-
39, respectively. The corresponding FAM probe was 59-
CGTTGCTCCATGGGCATGTAGTTG-39. The 18s primer
and probe sequences were homologous for mouse, rat, and human
(Forward: 59-AGAAACGGCTACCACATCCA-39; reverse: 59-
CTCGAAAGAGTCCTGTATTGT-39). The 18s TET probe was
59-AGGCAGCAGGCGCGCAAATTAC-39. Samples were ana-
lyzed using the ABI Prism 7700 sequence detection system
(Applied Biosystems). Data were analyzed using the relative
standard curve method described in the product manual.
Additionally, mRNA expression of hamster CD36 (F: 59-
TCAAGGGCATTGGGCAAACAGG-39 and R: 59-ATGG-
CACCGCTCTGCTCAAAC-39) was determined using Absolute
SYBR Green Fluorescein (Thermo Scientific) PCR mix in an
iCycler Thermal Cycler instrument (Bio-Rad) with hamster
GAPDH as a control (F: 59-ACGTGTCCGTTGTGGATCT-
GAC-39 and R: 59-CACCACCTTCTTGATGTCCTCATAC-
39). Data were analyzed using the comparative CT method.
Results
CHO-GPAT1 cells contained higher intracellular levels of
LPA than CHO cells
Rat GPAT1 expression was detected only in the overexpressing
cell line (data not shown) with a cycle threshold average of 18.3
(n=3). Mass spectrophotometry analysis showed that compared
with the CHO cells, CHO-GPAT1 cells contained 93% less acyl-
CoA, the substrate for GPAT1 (Table 1), and 6-times more LPA,
the product of GPAT1. DAG in CHO-GPAT1 cells was 41.5%
lower than in the CHO cells.
Overexpression of GPAT1 in CHO cells increased PPARc
activation
To determine whether the increased intracellular content of LPA
in the CHO-GPAT1 cells activated PPARc, CHO cells and CHO-
GPAT1 cells were transfected with a PPARc expression vector and
a PPRE-CAT reporter vector. PPARc activity was 6-fold higher in
CHO-GPAT1 cells than in the CHO control cells (Fig. 2A). The
PPARc ligand troglitazone increased PPARc activity 4-fold in
CHO cells and an additional 4-fold in the CHO-GPAT1 cells.
In both CHO and CHO-GPAT1 cells, PPARc activity increased
with increasing troglitazone concentrations up to 5 mM( Fig. 2B).
With all treatments, the CHO-GPAT1 overexpressing cells showed
a 4- to 10-fold higher PPARc activity than their CHO cell
counterparts. Because 1 mM troglitazone elicited a near maximal
response, it was used for all subsequent experiments. Additionally,
mRNA expression of CD36, a PPARc target, was elevated 2-fold in
GPAT1-CHO cells (Fig. 2C), suggesting a functional increase in
PPARc activity in GPAT1-overexpressing cells. Studies with a
PPARb/d expression vector showed very low relative CAT activity
in both cell lines, so these isoforms were not investigated further. A
PPARa expression vector showed no change in relative CAT
activity in the two cell lines, and stimulation with linoleic acid or
1 mM of the PPARa-specific activator Wy14643 did not show a
differential effect (data not shown).
Adding AGPAT2 to CHO-GPAT1 cells decreased PPARc
activity
In order to determine whether the increased PPARc activity in
CHO-GPAT1 cells was due to increased intracellular LPA, cells
were co-transfected with a 1-acylglycerol-3-phosphate acyltrans-
ferase-2 (AGPAT2) expression vector in order to convert LPA to
PA and diminish the LPA signal (Fig. 1) [16]. Adding the
AGPAT2 expression vector markedly lowered PPARc activity in
both CHO control and CHO-GPAT1 cells treated with either the
Table 1. Overexpression of GPAT1 in CHO cells increased
intracellular levels of LPA, and lowered the content of acyl-
CoA and DAG.
Lipid intermediates
(nmol/g protein) CHO CHO-GPAT1
Acyl-CoA 5666317 38 *
Lysophosphatidic acid 236638 14286241 *
Diacylglycerol 76086183 445261319 *
Lipid intermediates in CHO and CHO-GPAT1 cells were analyzed by mass
spectrometry as described in Methods. Lysophosphatidic acid and
diacylglycerol results are expressed as the mean 6 SD; n=3. The acyl-CoA result
for CHO-GPAT1 is the average of 2 measurements (32 and 45); * p,0.01.
doi:10.1371/journal.pone.0018932.t001
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decrease in PPARc activity was consistent, although the extent
of the decrease varied due to variation of luciferase sensitivity
between experiments (compare Fig. 3A and 3B).
Converting DAG to PA decreased PPARc activity
Because DGKa catalyzes the phosphorylation of DAG to form
PA, the transfection of constitutively active diacylglycerol kinase a
(DGKa) either alone or together with AGPAT2, allowed us to
analyze the effects of increasing cellular PA and of decreasing both
LPA and DAG (Fig. 1). Co-transfecting AGPAT2 plus constitutively
active DGKa lowered PPARc activation similar to AGPAT2 alone
and decreased the effect of troglitazone in both cell lines (Fig. 3B).
CHO-GPAT1 cells transfected with DGKa alone showed a PPARc
response similar to cells co-transfected with both AGPAT2 and
DGKa, a result which is consistent with inhibition of PPARc by PA.
Of interest is the recent report that cyclic phosphatidic acid is an
inhibitor of PPARc [22]. Regardless of treatment, PPARc activity
remained higher in CHO-GPAT1 cells than in CHO cells.
LPA and PA displace [
3H]rosiglitazone
Radioactive competitive binding assays confirmed that LPA was
a PPARc ligand. Palmitoyl-LPA, oleoyl-LPA, 1-palmitoyl, 2-
oleoyl-PA, and 1,2 dioleoyl-PA competitively displaced between
20–30% of [
3H]rosiglitazone with micromolar affinity from the
PPARc ligand binding domain (Table 2), as described previously
[4,5]. PA appeared to be more potent than LPA, but LPA binding
was similar to that described in previous reports [4,5].
Extracellular addition of LPA, PA, or diC8:0 did not
increase PPARc activity
LPA is formed from membrane phospholipids by phospholipases
D and A2 and regulates internal signaling pathways via G protein-
coupled cell surface receptors [3,23,24]. LPA entry into cells is
problematic. Entry is inhibited by albumin [6] and by cell-specific
enzymes like ecto-lipid phosphate phosphohydrolase (LPP) [25].
Exogenously provided LPA can activate a G protein-coupled
signaling pathway that may affect PPARc activity [3]. For example,
extracellular LPA inhibits adipogenesis via the LPA1 receptor [26],
and the LPA1 receptor is expressed by CHO cells [24]. In order to
make certain that the effects on PPARc were not due to effects of
external LPA or PA on G protein-coupled receptors and to learn
whether DAG might be playing a role in the observed effects, we
addedLPA,PA,ordioctanoylglyceroltotheculturemedium(Fig.4).
Dioctanoylglycerol is a cell permeable DAG [27], and intact PA does
not enter cells [28]. Compared with the vehicle control, these
additions had no effect on PPARc activity. Thus, neither DAG, LPA
nor PA added externally were able to increase PPARc activity.
Figure 2. Overexpression of GPAT1 in CHO cells activated PPARc. (A) CHO and CHO-GPAT1 cells were transfected with 0.1 mg of pRLSV40
(internal LUC control) and equal concentrations (0.4 mg) of a PPARc expression vector, an RXR expression vector, and a PPRE-CAT reporter vector for
24 h, then treated with either 5 mM troglitazone or vehicle (dimethylsulfoxide). (B) CHO and CHO-GPAT1 cells were similarly transfected with the
describedvectors,thentreatedwitheithervehicleortroglitazone(0.1 mMto5mM).CATactivity24 hlaterwasnormalizedtoLUCactivity(mean+/-SEM;
n=3) and expressed as relative CAT activity. Results are representative of three and two independent experiments, respectively. (C) CHO and CHO-
GPAT1 cells were grown in MEM as described in the methods. RNA was extracted, and CD36 expression was determined by qRTPCR and normalized to
GAPDH expression. Data represent the average of four separate experiments. *p,0.05 and **p#0.01 when comparing within treatment groups.
doi:10.1371/journal.pone.0018932.g002
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activity
Because the effects of GPAT1 and troglitazone were synergistic,
we wondered whether PPARc ligands like polyunsaturated fatty
acids might act similarly. PPARc activity is strongly activated by
12:0 and 18:2 and weakly activated by 18:1 and 16:0 [13]. In
CHO cells, both troglitazone and 18:2 increased PPARc activity
2-fold compared to the vehicle control, but other fatty acids were
less effective (Fig. 5). In the CHO-GPAT1 cells, 18:2 and
troglitazone treatments were also equivalent; each increased
PPARc activity 3- to 4-fold compared to the vehicle. None of
the other fatty acids had an effect greater than treatment with the
vehicle alone.
Discussion
LPA, an intermediate in the glycerol-3-phosphate pathway of
glycerolipid synthesis had previously been identified as a PPARc
ligand and agonist [4,5], but when added exogenously, it required
tridentate sulfonamid or dimethyl sulfoxide to enhance its entry
into RAW264.7 or CV-1 cells [4,6]. Evidence for functional
activation of PPARc by exogenously added LPA was inferred by
an increase in the PPARc target CD36 on the surface of primary
human monocytes [4]. However, because LPA does not readily
enter cells, the physiological significance of these observations has
remained uncertain.
Our study confirmed previous reports that showed that LPA
can partially displace [
3H]rosiglitazone [4,5] and suggested the
possibility that the PPARc binding site might simultaneously
Figure3. Adding AGPAT2and DGKato CHO-GPAT1 cells decreased PPARc activity. (A) CHO and CHO-GPAT1 cells were transfected with 0.1 mg
of pRLSV40 (internal LUC control), and equal concentrations (0.4 mg) of expression and reporter vectors, PPARc RXR, PPRE-CAT, and either empty vector or
an AGPAT2 expression vector. (B)Cells were similarly transfectedwiththe vectors describedpluseither awild-type(inactive) DGKaexpressionvector (2)o r
the constitutively active DGKaD 196 expression vector (+). Twenty-four hours after transfection, cells were treated with either vehicle or 1 mMt r o g l i t a z o n e .
CAT activity was measured 24 h later and normalized to LUC activity. The results (mean +/2 SEM; n=3) are expressed as relative CAT activity. Results are
representative of three and two independent experiments, respectively. *p,0.05 and **p#0.01 when comparing within treatment groups.
doi:10.1371/journal.pone.0018932.g003
Table 2. LPA and PA displace [
3H]rosiglitazone from PPARc-
LBD.
Glycerolipid species
Percent displacement of
[
3H]rosiglitazone
sn-1-18:0-LPA 25.961.5
sn-1-16:0-LPA 29.661.2
sn-1, 2-di18:1-PA 24.260.8
sn-1-16:0, 2-18:1-PA 21.760.9
Increasing concentrations of lipids were evaluated for the ability to displace
[
3H]rosiglitazone from PPARc LBD. LPA, lysophosphatidic acid; PA, phosphatidic
acid. The results are expressed as the mean 6 SEM; n=4 at 100 mM.
doi:10.1371/journal.pone.0018932.t002
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binding provides a possible explanation for the synergistic effect of
troglitazone and LPA as well as for the apparent inhibitory effect
of PA on PPARc-mediated expression of CAT activity. We
attribute the increase in PPARc activity to the increased LPA
levels since it is known that LPA can compete with the selective
PPARc ligand rosiglitazone for binding to PPARc [4], and as little
as 1 nM of the ether analog AGP is able to displace ,45% of
bound [
3H]rosiglitazone [5]. However, our results also showed
that the overexpression of GPAT1 in CHO cells enhanced the
effect of troglitazone on PPARc activity, suggesting that
troglitazone and LPA worked synergistically to enhance PPARc
activity. Synergistic enhancement is consistent with the suggestion
that rosiglitazone and AGP bind tightly to PPARc and that their
binding sites, although overlapping, are not in the same position,
since the two ligands cannot fully displace each other [5]. A less
likely possibility is that LPA might act indirectly by modifying the
function of a PPARc coactivator.
Despite studies that show direct LPA binding to PPARc, LPA
molecules that are produced within cells via a pathway of de novo
synthesis have not previously been considered to function as
PPARc agonists [29]. In order to investigate this possibility, we
used a CHO cell line that stably overexpresses GPAT1 [12].
These cells have a 3.8-fold increase in GPAT1 activity and contain
a higher triacylglycerol mass than control cells, suggesting that the
intermediates of glycerolipid synthesis, including LPA, might be
elevated. This hypothesis was confirmed by a mass spectropho-
tometric analysis that showed a 6-fold increase in LPA levels in the
CHO-GPAT1 cells and acyl-CoA levels 93% lower than those in
control CHO cells. These results are opposite those observed in
Gpat1
2/2 mice in which the liver LPA content is 50% lower and
acyl-CoA content is 3-fold higher than in wild type controls [10].
Because CHO-GPAT1 cells have higher levels of LPA and TAG,
we also expected to find increased DAG content, but DAG was
50% lower in the overexpressing cell line, perhaps because it was
rapidly converted to TAG [12].
Decreased PPARc activity has also been observed in another
study in which cells were transiently transfected with an AGPAT2
expression vector and then treated with extracellular LPA; in that
study, however, AGPAT expression did not inhibit PPARc in cells
treated with rosiglitazone or two other PPARc agonists [4]. In
contrast, our study showed that the AGPAT2 expression vector
markedly lowered PPARc activity even in the presence of
troglitazone, suggesting the possibility that PA, endogenously
synthesized by AGPAT, may inhibit PPARc. On the other hand,
PA may have had an inhibitory effect in our study, only because
we used troglitazone, a relatively weak PPARc ligand.
LPA can regulate a variety of signaling pathways within cells by
binding to G protein-coupled receptors located on the cell surface
[30], and it was possible that the effects on PPARc might be
mediated by this type of pathway if the LPA synthesized by
GPAT1 could cross the plasma membrane to leave the cell and
then interact with LPA1 receptors present on the plasma
membrane [24]. In order to ascertain whether the increased
PPARc activity we observed in CHO-GPAT1 cells was due to
intracellular versus secreted LPA, we added LPA to the medium.
Because externally added LPA had no effect on the PPARc
reporter, endogenous and intracellular LPA must have activated
PPARc.
In order to increase the LPA pool available to activate PPARc,
CHO and CHO-GPAT1 cells were transfected with the PPARc
expression vector and PPRE-CAT reporter and then treated with
different fatty acids at 250 mM. Although 18:2 strikingly increased
PPARc activity in the CHO-GPAT1 cells, the observed increase
in PPARc activity in this and other studies [13] might be due
either to direct binding of the fatty acid to PPARc or to an
increase in the total amount of LPA available as an agonist.
Figure 4. Treating CHO and CHO-GPAT1 cells with LPA, PA, or
DiC8:0 did not enhance PPARc activity. CHO and CHO-GPAT1 cells
were transfected with 0.1 mg of pRLSV40 (internal LUC control), and
equal concentrations (0.4 mg) of a PPARc expression vector, an RXR
expression vector, and a PPRE-CAT reporter vector. Twenty-four hours
later, the transfected cells were treated with vehicle (0.1% BSA), 1 mM
troglitazone, 5 mM oleoyl-LPA, 5 mM dioleoyl-PA, or 10 mM DiC8:0. CAT
activity was measured 24 h later and normalized to LUC activity. The
results (mean +/2 SEM; n=3) are expressed as relative CAT activity.
Results are representative of two independent experiments. *p,0.05
and **p#0.01 when comparing within treatment groups.
doi:10.1371/journal.pone.0018932.g004
Figure 5. Overexpression of GPAT1 in CHO cells enhanced the
effects of fatty acid treatments on PPARc activity. CHO and CHO-
GPAT1 cells were transfected with 0.1 mg of pRLSV40 (internal LUC
control), and equal concentrations (0.4 mg) of a PPARc expression
vector, an RXR expression vector, and a PPRE-CAT reporter vector, as
described. Twenty-four hours later, transfected cells were treated with
either vehicle (0.1% BSA), 1 mM troglitazone, or 250 mM fatty acid (lauric
acid (12:0), myristic acid (14:0), palmitic acid (16:0), oleic acid (18:1), or
linoleic acid (18:2)). CAT activity was measured 24 h later and
normalized to LUC activity. The results (mean +/2 SEM; n=3) are
expressed as relative CAT activity and are representative of two
independent experiments. Results were analyzed by ANOVA and
individual comparisons by Fischers LSD test for multiple comparisons.
doi:10.1371/journal.pone.0018932.g005
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agonist when it is formed intracellularly as an intermediate in the
glycerolipid biosynthetic pathway. This finding is important in
light of the current focus on the association of obesity and hepatic
steatosis, because stimulation of PPARc by thiazolidinedione
drugs like troglitazone alleviates insulin resistance [31]. In hepatic
steatosis, both PPARc and GPAT1 are normally upregulated
[32,33], and adenovirus-mediated overexpression of GPAT1 in rat
liver promotes the development of hepatic steatosis within 5–7
days [11]. Upregulation of GPAT1 increases its LPA product [11],
which could physiologically synergize with other PPARc ligands to
enhance hepatic steatosis. In a related study in which Gpat1
2/2
mice were crossed with ob/ob mice, hepatic TAG content was
reduced by 59% [34], suggesting that GPAT1 is responsible for
most of SREBP-1 regulated hepatic TAG accumulation. In the
current study, upregulation of PPARc is supported by an increase
in the PPARc target CD36. Although our study used cells that
stably over-express GPAT1, GPAT specific activity in the CHO-
GPAT1 cells is considerably lower than that normally measured in
liver and adipocytes. Thus, the enhanced activity of GPAT that
activated PPARc activity in this study is relevant to GPAT specific
activities that are normally present in the major lipogenic tissues.
Our study showing synergism between LPA and troglitazone
also suggests that different ligands activating a common nuclear
receptor may induce different effects, including different sets of
genes and biological activities [1]. Future experiments to test the
physiological effects of LPA generated by GPAT will require the
use of mammalian cells that have both a high expression of
PPARc and a low activity of GPAT that can be enhanced by
transfection.
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